Pulmatrix (PULM): Oct 27 Form 8-K Shareholder Vote, iSPERSE Pipeline & Biotech Peer Comparison vs. OCGN, INO, SGMO
PULM
Pulmatrix, Inc. (Nasdaq: PULM) is a clinical-stage biopharmaceutical company developing inhaled therapeutic products utilizing its patented iSPERSE engineered dry-powder inhalation delivery technology across central nervous system (CNS) and respiratory indications. On October 27, 2026, Pulmatrix filed a Current Report on Form 8-K (Item 5.07) disclosing the results of its shareholder vote.
Trading at a $5.73 million Nasdaq market capitalization, Pulmatrix is priced near cash and public shell enterprise value while holding clinical-stage assets including PUR3100 (inhaled dihydroergotamine for acute migraine, cleared for Phase 2) and respiratory antifungal and COPD candidates. Across small-cap biotech peers such as Ocugen (OCGN), Inovio (INO), and Sangamo (SGMO), non-dilutive partnering and strategic corporate combinations remain the primary drivers of valuation re-ratings.
Sector Peer Valuation & Catalyst Comparison
| Ticker | Company | Exchange | Market Cap | Primary Catalyst & Sector Focus |
|---|---|---|---|---|
| PULM (Subject) | Pulmatrix, Inc. | Nasdaq | $5.73M | Form 8-K (2026-10-27) · Clinical-Stage Respiratory & CNS Drug Delivery (iSPERSE) |
| $OCGN | Ocugen, Inc. | Nasdaq | $260M | Gene therapies & mucosal inhalation vaccine delivery |
| $INO | Inovio Pharmaceuticals, Inc. | Nasdaq | $98.0M | DNA medicines & respiratory papillomatosis therapeutics |
| $SGMO | Sangamo Therapeutics, Inc. | Nasdaq | $115M | Genomic medicines & neurology licensing partnerships |
Verified SEC EDGAR Filing Metrics (PULM · CIK 0001574235)
| Form | Filing Date | Disclosure Scope | EDGAR Source |
|---|---|---|---|
| 8-K | 2026-10-27 | SEC Form 8-K (Items: 5.07) | View EDGAR Filing → |
| 10-Q | 2026-08-13 | SEC Form 10-Q | View EDGAR Filing → |
| 8-K | 2026-08-13 | SEC Form 8-K (Items: 2.02,9.01) | View EDGAR Filing → |
| S-3 | 2026-06-04 | SEC Form S-3 | View EDGAR Filing → |
| 10-Q | 2026-05-15 | SEC Form 10-Q | View EDGAR Filing → |
What Active Traders & Microcap Desks Are Watching Next
Biotech catalyst traders and healthcare special-situations funds in our vault are tracking: (1) post-vote corporate strategy execution following the October 27 Form 8-K, (2) partnering or monetization updates for PUR3100 and PUR1900, and (3) quarterly cash burn discipline.
Primary sources (SEC EDGAR)
PULM Form 8-K (2026-10-27): https://www.sec.gov/Archives/edgar/data/1574235/000149315226048644/form8-k.htmPULM Form 10-Q (2026-08-13): https://www.sec.gov/Archives/edgar/data/1574235/000149315226037594/form10-q.htmPULM Form 8-K (2026-08-13): https://www.sec.gov/Archives/edgar/data/1574235/000149315226037592/form8-k.htmPULM Form S-3 (2026-06-04): https://www.sec.gov/Archives/edgar/data/1574235/000149315226027179/forms-3.htmSee the dilution and promotion flags before you see the pitch.
Each week: the micro and small-caps now showing dilution or paid-promotion signals, with the SEC filing behind every flag. No recommendations, no price targets.